2145109-70-0
2145109-70-0
Chemical Structure
Praluzatamab
Synonym(s): CX-191; CX-2009 Antibody
- CAS No.: 2145109-70-0
- Formula:N/A
- Molecular Weight:(146.9 kDa)
IUPAC Name: sodium 3-(methyl-d3)-2-oxopentanoate-4,4,5,5,5-d5
SMILES: [Praluzatamab]
Biological Activity: Praluzatamab is a monoclonal antibody targeting the activated leukocyte cell adhesion molecule (ALCAM/CD116). Praluzatamab can be used to synthesize Praluzatamab ravtansine (antibody-drug conjugates). Praluzatamab can be used for research of cancers[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Praluzatamab | 99.14% | Praluzatamab is a monoclonal antibody targeting the activated leukocyte cell adhesion molecule (ALCAM/CD116). Praluzatamab can be used to synthesize Praluzatamab ravtansine (antibody-drug conjugates). Praluzatamab can be used for research of cancers. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Martín-Sabroso C, et al. Antibody-Antineoplastic Conjugates in Gynecological Malignancies: Current Status and Future Perspectives. Pharmaceutics. 2021 Oct 15;13(10):1705. [Content Brief]
- [2]. Chomet M, et al. The tumor targeting performance of anti-CD166 Probody drug conjugate CX-2009 and its parental derivatives as monitored by 89Zr-immuno-PET in xenograft bearing mice. Theranostics. 2020 Apr 27;10(13):5815-5828. [Content Brief]
